Trial Profile
Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Infliximab (Primary) ; Methylprednisolone
- Indications Arthritis
- Focus Therapeutic Use
- Acronyms SOKS
- 10 May 2016 Status changed from recruiting to discontinued as were unable to recruit participants.
- 13 Oct 2010 New trial record